Why did GNCA stock fall to $0.0001

GNCA stock fell due to Genocea’s Chapter 11 reorganization history, stalled clinical catalysts, and very low liquidity. These factors created strong selling pressure and price gaps that pushed shares to **$0.0001**.

What is Meyka AI’s grade for GNCA stock

Meyka AI rates GNCA **62.62/100**, Grade **B**, Suggestion **HOLD**. The grade uses benchmark, sector, financial growth, metrics, forecasts and analyst signals; it is informational, not investment advice.

What is the 12‑month GNCA stock forecast

Meyka AI's forecast model projects a base 12‑month target of **$0.0010**, implying **900.00%** upside versus the current **$0.0001**. Forecasts are model‑based projections and not guarantees.

What are the main risks for GNCA stock

Main risks include potential delisting, continued clinical trial failures, cash burn, and low trading liquidity. Any of these can keep GNCA stock near current lows or push it lower.

US Stocks

GNCA Genocea Biosciences (NASDAQ) $0.0001 on 26 Feb 2026: Top loser signals to watch

ByDanny Kontos February 27, 2026

GNCA stock collapsed to $0.0001 on 26 Feb 2026 as trading closed on the NASDAQ in the United States. The drop of -97.44% from the prior close reflects near-zero liquidity and lingering fallout from Genocea Biosciences, Inc.’s Chapter 11 reorganization and prolonged clinical uncertainty. Volume was 30,268 shares versus a 50-day average price of $0.00 and a 200-day average of $0.11, underscoring thin trading. This piece breaks down the drivers, key ratios, Meyka AI grade, and a short-term forecast to help investors assess GNCA stock risk and any possible recovery scenarios.